Healthcare
Covalon Technologies Ltd.(CVALF)
Live Price
Offline$1.54
+0.00% today
1Y Change
-11.49%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $50.00M
- Revenue Growth
- +5.3%
- EPS Growth
- -31.6%
- Dividend Yield
- 8.2%
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Covalon Technologies Ltd. (CVALF) is a Healthcare stock with a market cap of $50.00M and listed on OTC. The stock last traded around $1.54 and down 11.5% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +5.3%, EPS growth of -31.6%, a dividend yield of 8.2%. What stands out right now is revenue +5.3%, EPS -31.6%, free cash flow -61.4% with operating margin 1.6% and ROIC 1.8%. The dividend matters to the case here, with a current yield around 8.2%. Valuation already assumes a fairly strong business story at P/E 51.9 and price/sales 1.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CVALF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+5.3% vs +7.6% peer median
Operating Margin
Below sector median
+1.6% vs +19.4% peer median
P/E
Above sector median
51.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 27, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +5.3% and EPS is at -31.6%, with operating margin around 1.6%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 8.2%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 27, 2026 | โ | +0.0% | -8.2% | โ |
2026 Feb 25, 2026 | -88.7% | +5.3% | +3.8% | -3.8% |
2025 Dec 11, 2025 | +134.8% | +0.0% | -1.6% | -2.3% |
Benchmark Edge
CVALF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CVALF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CVALF Max Drawdown
-44.29%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CVALF and SPY.
Company Overview
Covalon Technologies Ltd.
OTC
Covalon Technologies Ltd. is a medical technology company that specializes in developing, licensing, and commercializing innovative healthcare products. The primary focus of the company is on advanced wound care and infection prevention solutions, addressing critical needs in the healthcare industry. Covalon's portfolio includes products that promote healing and reduce the risk of infection, such as advanced dressings and protective surgical solutions. The company's offerings cater to a broad range of medical sectors, including hospitals, long-term care facilities, and home health care, ensuring patient safety and improving clinical outcomes. Covalon Technologies stands out through its commitment to research and development, leading to patented technologies that enhance the effectiveness and user-friendliness of its solutions. With a strong presence in North America and growing international reach, Covalon plays a vital role in the healthcare market by providing clinicians and caregivers with reliable products that support efficient medical care. Its innovative approach not only supports day-to-day medical procedures but also contributes to cost-effectiveness by potentially reducing complications and hospital stays.
- Leadership
- Mr. Brent Ashton
- Street Address
- 1660 Tech Avenue, Unit 5
- Mailing
- Mississauga, ON, L4W 5S7
- Region
- Mississauga, ON, Canada
- Last Updated
- May 9, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 51.9
- EV/EBITDA
- 24.3
- Price/Sales
- 1.6
- Price/Book
- 1.9
Growth
- Revenue
- +5.3%
- EPS
- -31.6%
- Free Cash Flow
- -61.4%
Profitability
- Gross Margin
- 51.6%
- Operating Margin
- 1.6%
- Net Margin
- 3.1%
- ROE
- 3.3%
- ROIC
- 1.8%
Balance Sheet
- Debt/Equity
- 0.08
- Current Ratio
- 5.69
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.